All News
RheumNow Podcast – Jack of All Subspecialties (10.1.2021)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
No Recurrent Cancer Risk With Biologic Treatment of RA
Patients with rheumatoid arthritis (RA) who had a history of cancer did not have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found.
Read Article
The #1 question I get from new consults: “How did I get arthritis?” Here is my list of 11 drugs (or drug classes) known to cause arthritis or rheumatic disorders (as an unintended consequence). #RheumNow https://t.co/GsV0Qj9ENr https://t.co/IrTkY5yFdY
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)
Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID breakthrough infections, and statin use and the risk of RA, as I review the news and journal articles from the past week on RheumNow.
Read Article
Guselkumab Treats Axial Disease in Psoriatic Arthritis
Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.
Read Article
11 Drugs That Cause Arthritis
This is the #1 question I get from new consults: “How did I get arthritis?”
But as the aching are asking, they are really thinking these joint complaints must be due to something.
Links:
Dr. John Cush RheumNow ( View Tweet)
IL-6 Inhibition in Refractory Systemic Sclerosis
A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)
Smartphones and diet; COVID-19 and the numbers - reassuring or not, and what about masks?; and do more drugs mean more switching, less persistence, and patient adherence goes up...or down? All this and more news and journal reports in this week's episode.
Read Article
Different Regimens but Equal Outcomes in Polyarticular JIA
CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
RheumNow Podcast – High Science and Future Treatments (9.10.2021)
This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Lymphoma in RA: Disease Activity Matters
Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.
In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for lymphoma, with an odds ratio of 2.09 (95% CI 1.41-3.38), according to Gaetane Nocturne, MD, of Hôpital Bicêtre in Ile-de-France, and colleagues.